Author:
Botrus Gehan,Miller Richard M.,Uson Junior Pedro Luiz Serrano,Kannan Geoffrey,Han Haiyong,Von Hoff Daniel D.
Abstract
High rates of cell proliferation and protein synthesis in pancreatic cancer are among many factors leading to endoplasmic reticulum (ER) stress. To restore cellular homeostasis, the unfolded protein response (UPR) activates as an adaptive mechanism through either the IRE1α, PERK, or ATF6 pathways to reduce the translational load and process unfolded proteins, thus enabling tumor cells to proliferate. Under severe and prolonged ER stress, however, the UPR may promote adaptation, senescence, or apoptosis under these same pathways if homeostasis is not restored. In this review, we present evidence that high levels of ER stress and UPR activation are present in pancreatic cancer. We detail the mechanisms by which compounds activate one or many of the three arms of the UPR and effectuate downstream apoptosis and examine available data on the pre-clinical and clinical-phase ER stress inducers with the potential for anti-tumor efficacy in pancreatic cancer. Finally, we hypothesize a potential new approach to targeting pancreatic cancer by increasing levels of ER stress and UPR activation to incite apoptotic cell death.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference76 articles.
1. American Cancer Society (2022, October 10). Facts & Figures 2022. American Cancer Society. Atlanta, Ga. Available online: https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html.
2. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy;Sarantis;World J. Gastrointest. Oncol.,2020
3. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results from a Multicenter, Prospective, Universal Genetic Testing Study;Uson;Clin. Transl. Gastroenterol.,2021
4. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer;Golan;N. Engl. J. Med.,2019
5. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin with or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation;Lee;J. Clin. Oncol.,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献